行业报告强生2023年第一季度报告1684136115_市场营销策划_重点报告20230503.docx

《行业报告强生2023年第一季度报告1684136115_市场营销策划_重点报告20230503.docx》由会员分享，可在线阅读，更多相关《行业报告强生2023年第一季度报告1684136115_市场营销策划_重点报告20230503.docx（15页珍藏版）》请在第一文库网上搜索。

1、WonFORIMMEDIATERE1EASEJohnson&JohnsonReportsQ12023Resu1ts 2023First-Quarterreportedsa1esgrowthof5.6%to$24.7Bi11ionwithoperationa1growthof9.0%*andadjustedoperationa1growthof7.6%* 2023First-Quarterbasic1osspershareof($0.03)decreasing101.6%duetoaspecia1one-timecharge,withadjustedearningspershare(EPS)of

2、$2.68increasingby0.4%* Companyisincreasing2023fu11-yearguidancemidpointsforadjustedoperationa1sa1esandadjustedoperationa1EPSNewBrunswick,N.J.(Apri118,2023)-Johnson&Johnson(NYSE:JNJ)todayannouncedresu1tsforfirst-quarter2023.0urfirstquarterresu1tsdemonstratestrongperformanceacrossa11threesegmentsofour

3、businessandref1ectthededicationofJohnson&Johnsonco11eaguesaroundthewor1d,saidJoaquinDuato1ChairmanoftheBoardandChiefExecutiveOfficer.*,Withthismomentum,I1ookforwardtotheremainderoftheyear,onefi11edwithexcitingcata1yststhatwi11createbothnear-and1ong-termva1ueforpatientsanda11ofourstakeho1ders.,OVERA1

4、1F1NANC1A1RESU1TSQ1($inMi11ions,exceptEPS)20232023%ChangeReportedSa1es$24,746$23,4265.6%NetEarningsZ(1oss)($68)$5,149(101.3)%EPS(basic/di1uted)5($0.03)$1.93(101.6)%Q1Non-GAAP($inMi11ions,exceptEPS)20232023%ChangeOperationa1Sa1es1129.0%AdjustedOperationa1Sa1es137.6%AdjustedNetEarnings14$7,068$7,129(0

5、.9)%AdjustedEPS(di1uted)4$2.68$2.670.4%iNon-GAAPfinancia1measure;refertorenci1iationsofnon-GAAPfinancia1measuresinc1udedinaccompanyingschedu1es2Exc1udestheimpactoftrans1ationa1currency3Exc1udesthenetimpactofacquisitionsanddivestituresandtrans1ationa1cency4Exc1udesintangib1eamortizationexpenseandspec

6、ia1items6Basicsharesareusedtoca1cu1ate1osspershareasuseofdi1utedshareswhenina1osspositionwou1dbeanti-di1utiveNote:va1uesmayhavebeenroundedREG1ONA1SA1ESRESU1TSQ1%Change($inMi11ions)20232023ReportedOperationa1Non-GAAPfinancia1measure;refertorenci1iationsofnon-GAAPfinancia1measuresinc1udedinaccompanyin

7、gschedu1es-Exc1udestheimpactoftrans1ationa1currencyCurrencyAdjustedOperationa11Exc1udesthenetimpactofacquisitionsanddivestituresandtrans1ationa1currencyNote:Va1uesmayhavebeenroundedU.S.$12,517$11,4149.7%9.77.4Internationa112,22912,0121.88.3(6.5)7.9Wor1dwide$24,746$23,4265.6%9.0(3.4)7.6Non-GAAPfinanc

8、ia1measure:refertoreconci1iationsofnon-GAAPfinancia1measuresinc1udedinaccompanyingschedu1es2 Exc1udestheimpactoftrans1ationa1currency3 Exc1udesthenetimpactofacquisitionsanddivestituresandtrans1ationa1currencyNote:Va1uesmayhavebeenroundedSEGMENTSA1ESRESU1TSQ1%Change($inMi11ions)20232023ReportedOperat

9、iona112CurrencyAdjustedOperationa113ConsumerHea1th$3,852$3,5867.4%11.3(3.9)11.3Pharmaceutica113,41312,8694.27.2(3.0)7.2MedTech7,4816,9717.311.0(3.7)6.4Wor1dwide$24,746$23,4265.6%9.0(3.4)7.6F1RSTQUARTER2023SEGMENTCOMMENTARY:Adjustedoperationa1sa1es*ref1ectedbe1owexc1udesthenetimpactofacquisitionsandd

10、ivestituresandtrans1ationa1currency.COnSUmerHea1thConsumerHea1thwor1dwideadjustedoperationa1sa1esincreased11.3%*1arge1ydrivenbyover-the-counter(OTC)products.MajorcontributorstogrowthinOTCwereTY1ENO1andMOTRINana1gesics,upperrespiratoryproducts,IMODIUMindigestivehea1thproductsandinternationa1smokingce

11、ssationproducts.Additiona1contributorstogrowthwereNEUTROGENAandAVEENOinSkinHeaIthZBeautyproductsandJOHNSONSinBabyCareproducts.PharmaCeUtiCa1Pharmaceutica1wor1dwideadjustedoperationa1sa1esgrew7.2%*,drivenbyDARZA1EX(daratumumab),abio1ogicforthetreatmentofmu1tip1emye1oma,STE1ARA(stekinumab),abio1ogicfo

12、rthetreatmentofanumberofimmune-mediatedinf1ammatorydiseases,ER1EADA(apa1utamide),anext-generationandrogenreceptorinhibitorforthetreatmentofpatientswithprostatecancer,CARVYKTI(Ci1tacabtageneauto1euce1),aBCMA-directedCAR-Timmunotherapyforthetreatmentofpatientswithre1apsedorrefractorymu1tip1emye1oma,an

13、dXARE1TO(rivaroxaban),adirectora1anticoagu1ant.A1socontributingtogrowthweresa1esoftheJanssenCOVID-19Vaccine(Ad26.COV2.S)forthepreventionoftheSARS-CoV-2Virus.Thisgrowthwaspartia11yoffsetbydec1inesinsa1esofREMICADE(inf1iximab),abio1ogicapprovedforthetreatmentofsevera1immune-mediatedinf1ammatorydisease

14、s,IMBRUVICA(ibrtinb),anora1,oncedai1ytherapyapprovedforuseintreatingcertainB-ce11ma1ignancies,atypeofb1oodor1ymphnodecancer,andZYTIGA(abirateroneacetate),anora1,oncedai1ymedicationforuseincombinationwithprednisoneforthetreatmentofmetastaticcastration-resistantprostatecancer.MedTeChMedTechwor1dwidead

15、justedoperationa1sa1esgrew6.4%*,drivenprimari1ybye1ectrophysio1ogyproductsinInterventiona1So1utions,contact1ensesinVision,woundc1osureproductsinGenera1Surgery,andkneesinOrthopaedics.MedTechwor1dwideoperationa1sa1esgrew11.0%*,withtheacquisitionofAbiomedcontributing4.6%.NOTAB1ENEWANNoUNCEMENTSINTHEQUARTER:Theinformationcontainedinthissectionshou1dbereadinconjunctionwithJohnson&Johnson,sotherdisc1osuresfi1edwiththeSecuritiesandExchangeCommission,inc1udingitsCurrentReportsonForm8-K,Quarter1yReportso